Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5'-deoxy-5-fluorocytidine (5'-DFCR) - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33874986/
doi: 10.1186/s13046-021-01938-2. 1 Department of General Thoracic Surgery, Inselspital, Bern University Hospital, Murtenstrasse 50, 3008, Bern, Switzerland. 2 Department of BioMedical Research, University of Bern, Bern, Switzerland. 3 Institute of...
-
KRAS Oncogene Connect5yrKey Points • Combined therapy with pemetrexed (MTA) and cisplatin in patients with advanced non-small cell lung cancer is the standard of care, however the 5-year survival rate is fewer than 10% Show More
In Vitro Anti-cancer Activity of Adipose-Derived Mesenchymal Stem Cells Increased after Infection with Oncolytic Reovirus - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33880359/
Purpose: Reovirus type 3 Dearing (ReoT3D), a wild type oncolytic virus (OV) from the Reoviridae family, kills KRAS mutant cancer cells. However, the use of OVs has faced with some...
Spatially interacting phosphorylation sites and mutations in cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33875650/
1 Department of Genetics and Genomics, Tisch Cancer Institute, Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. [email protected]. 2...
SOD1 regulates ribosome biogenesis in KRAS mutant non-small cell lung cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33859191/
SOD1 is known as the major cytoplasmic superoxide dismutase and an anticancer target. However, the role of SOD1 in cancer is not fully understood. Herein we describe the generation of...
42-Year-Old Non-Smoker Diagnosed with NSCLC
Samantha is a 42-year-old mother of two. She was athletic — playing basketball in college and running mini-marathons in her 30s. She ran her first full marathon just months before she was diagnosed with NSCLC.
Severe shoulder pain prompted Samantha to go to the ER. A thoracic X-ray was suggestive...
-
Thomas Barton5yrclinical trial with KRAS G12C inhibitor
-
Anonymous User5yr@Kumar - while I agree the standard of care is clear, my message was to develop a clinical trial to solve the question, unless the data from PACIFIC already included Show More